GlassScriptPhysician profile
Priti Palvadi
NPI 1700992641
$9,402.52
in general payments reported to CMS, 2019-2025
66 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,684 · 2020: $522 · 2021: $605 · 2022: $584 · 2023: $2,581 · 2024: $1,128 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $858.44 | 2019-2025 | |
| Emd Serono, INC. | $650.79 | 2019-2025 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $476.43 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $420.17 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $350.91 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Harmony Biosciences LLC | $334.46 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $301.61 | 2019-2025 | Xywav |
| Acadia Pharmaceuticals INC | $238.57 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $238.25 | 2019-2025 | Ongentys, Ingrezza |
| Pfizer INC. | $228.59 | 2023-2025 | |
| Lundbeck LLC | $210.23 | 2019-2025 | Rexulti, Vyepti |
| Sk Life Science, INC. | $208.19 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $202.15 | 2023-2025 | Rexulti |
| Acorda Therapeutics, INC | $199.34 | 2019 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $193.08 | 2023 | Vyvgart |
| Assertio Therapeutics, INC. | $184.67 | 2019 | |
| Csl Behring | $172.25 | 2019-2023 | Hizentra |
| Ucb, INC. | $143.58 | 2019-2025 | Briviact, Rystiggo |
| Abbott Laboratories | $140.12 | 2023-2025 | Infinity, Confirm Rx |
| Adamas Pharmaceuticals, INC. | $138.47 | 2019-2020 | |
| Lilly USA, LLC | $123.01 | 2019-2023 | Reyvow, Emgality |
| Inspire Medical Systems, INC. | $113.30 | 2023-2024 | Inspire |
| Allergan, INC. | $106.12 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $102.80 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $101.03 | 2021-2024 | Acthar |
| Janssen Biotech, INC. | $99.95 | 2025 | |
| Genzyme Corporation | $99.31 | 2019-2021 | |
| Genentech USA, INC. | $95.19 | 2022-2023 | Ocrevus |
| Springworks Therapeutics, INC. | $90.64 | 2024-2025 | Gomekli |
| Livanova USA, INC. | $84.88 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $84.72 | 2019-2023 | |
| Ge Healthcare | $83.91 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $77.72 | 2023 | Aptiom |
| Octapharma USA, INC. | $76.78 | 2023 | Octagam Immune Globulin (Human) |
| Amneal Pharmaceuticals LLC | $76.05 | 2019-2025 | Rytary, Crexont |
| Ani Pharmaceuticals, INC. | $74.77 | 2023-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $72.22 | 2024-2025 | Sunosi, Symbravo |
| Tanabe Pharma America, INC. | $70.84 | 2019-2024 | |
| Boston Scientific Corporation | $70.50 | 2024 | Vercise |
| Kyowa Kirin, INC. | $68.02 | 2019-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $65.94 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $60.14 | 2024-2025 | Lumryz |
| Corium, LLC | $59.59 | 2023 | Adlarity |
| Merz North America, INC. | $47.92 | 2019 | |
| Merz Pharmaceuticals, LLC | $47.16 | 2023 | Xeomin |
| Amgen INC. | $44.21 | 2020-2021 | |
| Promius Pharma LLC | $37.29 | 2019 | |
| Grifols USA, LLC | $36.23 | 2019 | |
| Azurity Pharmaceuticals, INC. | $33.77 | 2023 | Horizant |
| Eisai INC. | $33.00 | 2019 | |
| Sandoz INC. | $32.85 | 2024 | |
| Arbor Pharmaceuticals, INC. | $31.84 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $31.77 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $29.00 | 2023 | Dysport |
| Akcea Therapeutics, INC. | $28.44 | 2019 | |
| Insightec,INC | $28.40 | 2023-2024 | Exablate |
| Biotronik Nro, INC. | $28.09 | 2025 | Prospera |
| Biohaven Pharmaceutical Holding Company LTD. | $25.82 | 2022 | |
| Nevro Corp. | $25.46 | 2023 | Senza |
| Shire North American Group INC | $23.16 | 2019 | |
| Resmed Corp | $22.17 | 2019 | |
| Aquestive Therapeutics, INC. | $18.48 | 2020 | |
| Zoll Respicardia, INC. | $17.97 | 2024 | Remede System |
| Vertical Pharmaceuticals, LLC | $16.98 | 2019 | |
| Almatica Pharma LLC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Palvadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.